Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.21 EUR
Change Today -0.007 / -3.21%
Volume 282.8K
As of 11:30 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

biotie therapies oyj (BTH1V) Snapshot

Open
€0.22
Previous Close
€0.22
Day High
€0.22
Day Low
€0.21
52 Week High
06/22/15 - €0.26
52 Week Low
05/12/15 - €0.14
Market Cap
206.2M
Average Volume 10 Days
2.3M
EPS TTM
€-0.08
Shares Outstanding
977.3M
EX-Date
03/30/06
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIE THERAPIES OYJ (BTH1V)

Related News

No related news articles were found.

biotie therapies oyj (BTH1V) Related Businessweek News

No Related Businessweek News Found

biotie therapies oyj (BTH1V) Details

Biotie Therapies Corp., a drug development company, focuses on the development of drugs for neurodegenerative and psychiatric disorders primarily in Finland and the United States. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; and Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which has completed in Phase II trial. The company’s products also comprise BTT1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 in Phase II development in fibrotic conditions and received orphan drug designation for the treatment of primary sclerosing cholangitis; and SYN120, an oral, potent, dual antagonist of the 5-HT6 and 5-HT2A receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose for subsequent Phase II studies. Biotie Therapies Corp. is based in Turku, Finland.

40 Employees
Last Reported Date: 06/12/15

biotie therapies oyj (BTH1V) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biotie therapies oyj (BTH1V) Key Developments

Biotie Therapies Corp.(NasdaqGS:BITI) added to NASDAQ Composite Index

Biotie Therapies Corp. has been added to Nasdaq Composite Index.

Biotie Therapies Corp. Announces Board Changes

Biotie Therapies Corp. announced that the terms of Don M. Bailey and Mahendra G. Shah as members of Biotie's Board of Directors commence and the number of Board members increases from five to seven. Following the addition of new Board members, the Board of Directors has determined the composition of its committees. Don M. Bailey was elected the Chairman and Bernd Kastler and Merja Karhapaa the members of the Board's Audit Committee. Furthermore, William Burns was elected the Chairman and Guido Magni, Ismail Kola and Mahendra G. Shah the members of the Nomination and Remuneration Committee. The Board of Directors has also elected Bernd Kastler as the Vice Chairman of the Board.

Biotie Therapies Corp Announces Agreement with FDA on a Special Protocol Assessment for Tozadenant Phase 3 Study

Biotie Therapies Corp. has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 study of tozadenant in Parkinson's disease (PD). The Phase 3 study (TOZ-PD) will evaluate efficacy and safety of tozadenant compared to placebo in PD patients taking levodopa and experiencing end-of-dose wearing off. A Special Protocol Assessment is a written agreement with the FDA on the design, size and planned analysis for a clinical trial. An SPA may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of new public health concerns. A positive outcome of TOZ-PD, along with the results of the completed Phase 2b study are expected to be sufficient to support a claim of efficacy for tozadenant in patients with Parkinson's disease with motor fluctuations (end-of-dose wearing off) and could form the basis of an NDA submission. Final marketing approval will be dependent, amongst other factors, on the overall results of the trial. The planned study is a randomized, double-blind, placebo controlled Phase 3 study in 450 PD patients experiencing levodopa related end-of-dose wearing off, in which participants will be randomized to receive twice daily doses of 60mg or 120mg of tozadenant or placebo, in addition to their standard anti-PD medications, for 24 weeks. The primary endpoint will be reduction in time spent in the "off" state in patients taking tozadenant as compared to placebo between baseline and week 24. The double-blind phase of the study will be followed by an open-label treatment phase of a one year duration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.21 EUR -0.007

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies
 

Industry Analysis

BTH1V

Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.